Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 1, 2011, Pages 53-59

  Nagy, Viorica Magdalena ^a,b   Buiga, R ^a   Brie, Ioana ^a,b   Todor, N ^a   Tudoran, Oana ^a,c   Ordeanu, Claudia ^a   Virág, Piroska ^a   Tarta, Oana ^a   Rus, Meda ^a   Balacescu O ^a  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c BABE BOLYAI UNIVERSITY   (Romania)

Author keywords

Angiogenesis; Biomarkers; Cervix cancer; Prediction

Indexed keywords

CYCLOOXYGENASE 2; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PTGS2 PROTEIN, HUMAN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; STROMA CELL; UTERINE CERVIX TUMOR; VASCULARIZATION;

ADULT; AGED; CYCLOOXYGENASE 2; FEMALE; HUMANS; MICROVESSELS; MIDDLE AGED; NEOPLASM STAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; ROC CURVE; STROMAL CELLS; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79953042737     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Globocan 2008. Cancer fact sheets: cervical cancer incidence and mortality worldwide in 2008, http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
2. Nagy V, Changes in natural history of cervical cancer through concomitant radio-chemotherapy, Radioter Oncol Med, 2003, IX(1):21-26.
3. Eifel PJ, Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer, Nat Clin Pract Oncol, 2006, 3(5):248-255.
4. Vieira SC, Zeferino LC, Da Silva BB, Aparecida Pinto G, Vassallo J, Carasan GA, De Moraes NG, Quantification of angiogenesis in cervical cancer: a comparison among three endothelial cell markers, Gynecol Oncol, 2004, 93(1):121-124.
5. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, Lee RJ, Zempolich K, Dodson M, Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy, Int J Radiat Oncol Biol Phys, 2003, 56(4):922-928.
6. Press MF, Lenz HJ, EGFR, HER2 and VEGF pathways: validated targets for cancer treatment, Drugs, 2007, 67(14):2045-2075.
7. Schenone S, Bondavalli F, Botta M, Antiangiogenic agents: an update on small molecule VEGFR inhibitors, Curr Med Chem, 2007, 14(23):2495-2516.
8. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM, Vascular endothelial growth factor (VEGF) expression as a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix, Br J Cancer, 2000, 83(5):620-625.
9. Ueda M, Terai Y, Kumagai K, Ueki K, Yamaguchi H, Akise D, Ueki M, Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells, Gynecol Oncol, 2001, 82(1):162-166.
10. Hashimoto I, Kodama J, Seki N, Hongo A, Yoshinouchi M, Okuda H, Kudo T, Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer, Br J Cancer, 2001, 85(1):93-97.
11. Kristensen GB, Holm R, Abeler VM, Tropé CG, Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous carcinoma. An immunohistochemical study, Cancer, 1996, 78(3):433-440.
12. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van de Vijver MJ, Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis, Clin Cancer Res, 1999, 5(3):577-586.
13. Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC, Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis, Tumour Biol, 2001, 22(3):176-183.
14. Nagai N, Oshita T, Fujii T, Kioka H, Katsube Y, Ohama K, Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer, Oncol Rep, 2000, 7(3):551-559.
15. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC, Oh KS, High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion, Gynecol Oncol, 2000, 76(3):320-325.
16. Ferrandina G, Lauriola L, DiStefano MG, Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A, Scambia G, Ranelletti FO, Increased cyclooxygenase-2 expression in associated with chemotherapy resistance and poor survival in cervical cancer patients, J Clin Oncol, 2002, 20(4):973-981.
17. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M, Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy, Int J Radiat Oncol Biol Phys, 2001, 49(5):1213-1217.
18. Gallo O, Re: Enhancement of tumor response to gammaradiation by an inhibitor of cyclooxygenase-2 enzyme, J Natl Cancer Inst, 2000, 92(4):346-347.
19. Obermair A, Wanner C, Bligi S, Speiser P, Kaider A, Reinthaller A, Leodolter S, Gitsch G, Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival, Am J Obstet Gynecol, 1998, 178(2):314-329.
20. Stewart M, Turley H, Cook N, Pezzella F, Pillai G, Ogilvie D, Cartlidge S, Paterson D, Copley C, Kendrew J, Barnes C, Harris AL, Gatter KC, The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study, Histopathology, 2003, 43(1):33-39.
21. Giatromanolaki A, Koukourakis MI, Turley H, Sivridis E, Harris AL, Gatter KC; Tumour and Angiogenesis Research Group, Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis, Mod Pathol, 2006, 19(5):701-707.
22. Fox SB, Turley H, Cheale M, Blázquez C, Roberts H, James N, Cook N, Harris A, Gatter K, Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus, J Pathol, 2004, 202(3):313-320.
23. Longatto-Filho A, Pinheiro C, Martinho O, Moreira MA, Ribeiro LF, Queiroz GS, Schmitt FC, Baltazar F, Reis RM, Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma, BMC Cancer, 2009, 9:212.
24. Kuemmel S, Thomas A, Landt S, Fuger A, Schmid P, Kriner M, Blohmer JU, Sehouli J, Schaller G, Lichtenegger W, Köninger A, Fuchs I, Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer, Anticancer Res, 2009, 29(2):641-646.
25. Baumann M, Krause, Dikomey E, Dittmann K, Dörr W, Kasten-Pisula U, Rodemann HP, EGFR-targeted anticancer drugs in radiotherapy: preclinical evaluation of mechanisms, Radiother Oncol, 2007, 83(3):238-248.
26. Smith WL, DeWitt DL, Garavito RM, Cyclooxygenases: structural, cellular, and molecular biology, Annu Rev Biochem, 2000, 69:145-182.
27. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN, Host cyclooxygenase-2 modulated carcinoma growth, J Clin Invest, 2000, 105(11):1589-1594.
28. Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, Park HC, Suh CO, Park TK, Kim BS, Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy, Cancer, 2002, 95(3):531-539.
29. Noriyuki M, Sumi T, Zhi X, Misugi F, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O, Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women, Int J Oncol, 2007, 31(3):531-536.